Minimal Protein from DNA Mini Circles Provides Therapeutic ...

1
Matthew Nitzahn 1,2 , Suhail Khoja 2 , Jenna Lambert 2 , Hiu Man Grisch-Chan 3 , Beat Thöny 3 , Gerald S. Lipshutz 1,2,4 Introduction Minimal Protein from DNA Mini Circles Provides Therapeutic Benefit in CPS1 Deficiency Carbamoyl phosphate synthetase 1 (CPS1) catalyzes the first committed step of the urea cycle, eliminating nitrogen waste Loss of CPS1 function results in toxic ammonia levels and encephalopathy, often leading to death Treatments for CPS1 deficiency are largely ineffective, and donor livers for transplantation are scarce AAV-based gene therapy is attractive, and we recently demonstrated its potential in a proof-of-concept study using split AAVs (Nitzahn 2020) To avoid expensive, intensive viral approaches, DNA mini circles (MCs) provide an alternative to investigate MCs containing human codon optimized CPS1 (hcoCPS1) driven by the CAG promoter were generated and conjugated to jetPEI-Gal (Polyplus) at nitrogen/phosphate ratio = 8 Adult female Cps1 flox/flox mice (Khoja 2018) were injected with AAV-Cre alone (control) or AAV-Cre + MCs (treated) at 1.6-2.4mg/kg MC in 4-5 doses Mice were weighed daily and given n-carglumic acid (200mg/L) in drinking water. Plasma was collected at regular intervals and at humane euthanasia time points from sick mice Livers were collected immediately after euthanasia for analysis Figure 1. Schematic of MC generation. A parental plasmid containing the transgenic cassette flanked by attB and attP recombination sites is generated and propagated in the specialized E. coli strain from Kay 2010. Induction of øC31- integrase with L-arabinose recombines the attB/P sites, forming the MC and daughter plasmid. I-SceI sites in the daughter are recognized and mediate its digestion, yielding pure MCs. Figure 2. Untreated mice perish while MC-treated survive. MC-treated mice had significantly longer survival than their untreated counterparts (p < 0.05). The treated mouse that expired receive the lowest dose (134μg vs. >170μg). n = 3 mice per group MCs expressing hcoCPS1 are sufficient to extend lifespan and reduce plasma ammonia in Cps1-deficient mice MC-treated mice have low gene and protein expression MC-derived protein is mainly localized to the perivasculature Kay, M. A et al. Nat Biotechnol 28, 12871289 (2010). Khoja, S. et al. Molecular Genetics and Metabolism 124, 243253 (2018). Nitzahn, M. et al. Molecular Therapy. In press (2020). Increase the number of mice to confirm that observed trends are statistically significant Expand treatment to include male mice, which may have differential response to therapeutics (Khoja 2018) Optimize dosing and administration strategies to maximize therapeutic benefits Funding for this work was provided by the UCLA Whitcome Pre-Doctoral Fellowship and R21NS091654 to GSL. The MC bacteria and empty parental plasmid were generous gifts from HMGC and BT. . Figure 4. MC-treated mice have extremely low CPS1 expression. Total DNA was extracted and the vector copy number determined in MC-treated mice (left); the ~14 value corresponds to the mouse that perished. Total RNA was also analyzed and compared to wild type mice (right). Treated mice show barely detectable levels of CPS1 expression, despite 2 of 3 showing no outward signs of poor health at the time to euthanasia. The highest expression was found in the mouse that perished. n = 3 treated, 5 wild type. Figure 3. MC-treated mice show reduced plasma ammonia. Mice treated with MCs trend towards reduced plasma ammonia compared to untreated controls. Plasma was not available from the treated mouse that perished. n = 2 per group; bars are mean ± SEM Methods Funding & Acknowledgments Conclusions Results Future Directions References 1 Molecular Biology Institute, 2 Surgery, 3 Molecular and Medical Pharmacology, UCLA ; 3 Division of Metabolism and Children’s Research Center, University Children’s Hospital Zurich Lab website: https://lipshutzlabucla.com/ KO MC 0 500 1000 1500 2000 Plasma Ammonia ( M) p = 0.096 0 10 20 30 40 0 50 100 Time (Days) Survival Untreated Treated Log-rank p<0.05 0 5 10 15 20 25 Vector Copy Number Per Diploid Genome MC WT 0.00000 0.00025 0.00050 0.00075 0.00100 1.0 1.5 CPS1 mRNA Expression p < 0.01 Figure 5. CPS1 protein expression and distribution in MC-treated mice. Top) Immunohistochemistry in mice treated with MCs (left 3 columns) shows bright, perivascular CPS1 expression with little distributed throughout the liver parenchyma. Wild type mice (far right column) have extensive, pan-hepatic CPS1 expression. The treated mouse that perished is on the far left. Bottom left) Western blot of MC-treated mice compared to wild type (WT). The treated mouse that perished is in lane 1. Protein levels are far below wild type levels in all treated mice. CPS1 β-actin MC-treated WT Contact: [email protected]

Transcript of Minimal Protein from DNA Mini Circles Provides Therapeutic ...

Page 1: Minimal Protein from DNA Mini Circles Provides Therapeutic ...

Matthew Nitzahn1,2, Suhail Khoja2, Jenna Lambert2, Hiu Man Grisch-Chan3, Beat Thöny3, Gerald S. Lipshutz1,2,4

Introduction

Minimal Protein from DNA Mini Circles Provides Therapeutic Benefit in CPS1 Deficiency

• Carbamoyl phosphate

synthetase 1 (CPS1) catalyzes

the first committed step of the

urea cycle, eliminating nitrogen

waste

• Loss of CPS1 function results

in toxic ammonia levels and

encephalopathy, often leading

to death

• Treatments for CPS1 deficiency

are largely ineffective, and

donor livers for transplantation

are scarce

• AAV-based gene therapy is

attractive, and we recently

demonstrated its potential in a

proof-of-concept study using

split AAVs (Nitzahn 2020)

• To avoid expensive, intensive

viral approaches, DNA mini

circles (MCs) provide an

alternative to investigate

• MCs containing human codon

optimized CPS1 (hcoCPS1)

driven by the CAG promoter

were generated and conjugated

to jetPEI-Gal (Polyplus) at

nitrogen/phosphate ratio = 8

• Adult female Cps1flox/flox mice

(Khoja 2018) were injected

with AAV-Cre alone (control)

or AAV-Cre + MCs (treated) at

1.6-2.4mg/kg MC in 4-5 doses

• Mice were weighed daily and

given n-carglumic acid

(200mg/L) in drinking water.

• Plasma was collected at regular

intervals and at humane

euthanasia time points from

sick mice

• Livers were collected

immediately after euthanasia

for analysis

Figure 1. Schematic of MC generation. A parental plasmid

containing the transgenic cassette flanked by attB and attP

recombination sites is generated and propagated in the

specialized E. coli strain from Kay 2010. Induction of øC31-

integrase with L-arabinose recombines the attB/P sites,

forming the MC and daughter plasmid. I-SceI sites in the

daughter are recognized and mediate its digestion, yielding

pure MCs.

Figure 2. Untreated mice perish while MC-treated survive.

MC-treated mice had significantly longer survival than their

untreated counterparts (p < 0.05). The treated mouse that

expired receive the lowest dose (134µg vs. >170µg). n = 3

mice per group

• MCs expressing hcoCPS1 are

sufficient to extend lifespan

and reduce plasma ammonia in

Cps1-deficient mice

• MC-treated mice have low

gene and protein expression

• MC-derived protein is mainly

localized to the perivasculature

Kay, M. A et al. Nat Biotechnol

28, 1287–1289 (2010).

Khoja, S. et al. Molecular

Genetics and Metabolism 124,

243–253 (2018).

Nitzahn, M. et al. Molecular

Therapy. In press (2020).

• Increase the number of mice to

confirm that observed trends

are statistically significant

• Expand treatment to include

male mice, which may have

differential response to

therapeutics (Khoja 2018)

• Optimize dosing and

administration strategies to

maximize therapeutic benefits

Funding for this work was

provided by the UCLA Whitcome

Pre-Doctoral Fellowship and

R21NS091654 to GSL.

The MC bacteria and empty

parental plasmid were generous

gifts from HMGC and BT.

.

Figure 4. MC-treated mice have extremely low CPS1

expression. Total DNA was extracted and the vector copy

number determined in MC-treated mice (left); the ~14 value

corresponds to the mouse that perished. Total RNA was also

analyzed and compared to wild type mice (right). Treated

mice show barely detectable levels of CPS1 expression,

despite 2 of 3 showing no outward signs of poor health at the

time to euthanasia. The highest expression was found in the

mouse that perished. n = 3 treated, 5 wild type.

Figure 3. MC-treated mice show reduced plasma

ammonia. Mice treated with MCs trend towards reduced

plasma ammonia compared to untreated controls. Plasma was

not available from the treated mouse that perished. n = 2 per

group; bars are mean ± SEM

Methods

Funding &

Acknowledgments

ConclusionsResults

Future Directions

References

1Molecular Biology Institute, 2Surgery, 3Molecular and Medical Pharmacology, UCLA ; 3Division of Metabolism and Children’s Research Center, University Children’s Hospital Zurich

Lab website: https://lipshutzlabucla.com/

KO MC

0

500

1000

1500

2000

Pla

sm

a A

mm

on

ia (

M)

p = 0.096

0 10 20 30 40

0

50

100

Time (Days)

Su

rviv

al

Untreated

TreatedLog-rankp<0.05

0

5

10

15

20

25

Vec

tor

Co

py N

um

ber

Per

Dip

loid

Gen

om

e

MC WT

0.00000

0.00025

0.00050

0.00075

0.00100

1.0

1.5

CP

S1 m

RN

A E

xp

ressio

n

p < 0.01

Figure 5. CPS1 protein expression and distribution in MC-treated mice. Top)

Immunohistochemistry in mice treated with MCs (left 3 columns) shows bright, perivascular

CPS1 expression with little distributed throughout the liver parenchyma. Wild type mice (far right

column) have extensive, pan-hepatic CPS1 expression. The treated mouse that perished is on the

far left. Bottom left) Western blot of MC-treated mice compared to wild type (WT). The treated

mouse that perished is in lane 1. Protein levels are far below wild type levels in all treated mice.

CPS1

β-actin

MC-treated WT

Contact: [email protected]